Bayer submits European marketing authorization application for darolutamide (for specialized target groups only)

Third submission for darolutamide in two weeks underscores Bayer’s commitment to fill an unmet need for men with nmCRPC worldwide / Regulatory submission based on positive data from Phase III study ARAMIS
Source: Bayer Company News - Category: Pharmaceuticals Source Type: news